Regulatory PathRegulatory requirements compared

Active substance

Zonisamide

Open in the medicines table

US FDA United States — FDA approvals (Drugs@FDA)

ProductStrengthForm · routeApplicantStatusFirst approved
ZONEGRAN100MG; 25MGcapsule · oralADVANZ PHARMAPrescription27 Mar 2000
ZONISAMIDE100MG; 50MG; 25MGcapsule · oralGRANULESPrescription22 Dec 2005
ZONISAMIDE100MG; 25MG; 50MGcapsule · oralAUROBINDO PHARMA LTDPrescription22 Dec 2005
ZONISAMIDE25MG; 50MG; 100MGcapsule · oralGLENMARK PHARMSPrescription30 Jan 2006
ZONISAMIDE25MG; 50MG; 100MGcapsule · oralINVAGEN PHARMSPrescription31 May 2006
ZONISAMIDE25MG; 50MG; 100MGcapsule · oralBIONPHARMAPrescription16 Aug 2006
ZONISAMIDE25MG; 50MG; 100MGcapsule · oralZYDUS LIFESCIENCESPrescription16 Oct 2006
ZONISAMIDE25MG; 50MG; 100MGcapsule · oralUNICHEMPrescription26 Jan 2021
ZONISADE100MG/5MLsuspension · oralAZURITYPrescription15 Jul 2022
ZONEGRAN50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**capsule · oralADVANZ PHARMADiscontinued27 Mar 2000
ZONISAMIDE25MG; 50MG; 100MGcapsule · oralSUN PHARM INDUSTRIESDiscontinued22 Dec 2005
ZONISAMIDE25MG; 50MG; 100MGcapsule · oralRISINGDiscontinued22 Dec 2005
ZONISAMIDE25MG; 50MG; 100MGcapsule · oralANI PHARMSDiscontinued22 Dec 2005
ZONISAMIDE100MG; 50MG; 25MGcapsule · oralANI PHARMSDiscontinued22 Dec 2005
ZONISAMIDE25MG; 50MG; 100MGcapsule · oralAPOTEXDiscontinued22 Dec 2005
ZONISAMIDE25MG; 50MG; 100MGcapsule · oralUPSHER SMITH LABSDiscontinued22 Dec 2005
ZONISAMIDE25MG; 50MG; 100MGcapsule · oralPHARMOBEDIENTDiscontinued22 Dec 2005
ZONISAMIDE25MG; 50MG; 100MGcapsule · oralROXANEDiscontinued22 Dec 2005
ZONISAMIDE25MG; 50MG; 100MGcapsule · oralSUN PHARM INDS (IN)Discontinued17 Mar 2006
ZONISAMIDE25MG; 50MG; 100MGcapsule · oralCHARTWELL RXDiscontinued20 Apr 2006
ZONISAMIDE25MG; 50MG; 100MGcapsule · oralEPIC PHARMA LLCDiscontinued21 Feb 2007
ZONISAMIDE25MG; 50MG; 100MGcapsule · oralMACLEODS PHARMSDiscontinued12 May 2025

EMA European Union — centrally authorised medicines

Zonegran Amdipharm Limited · Authorised · authorised 10 Mar 2005 · ATC N03AX15

Therapeutic indication (EMA)

Zonegran is indicated as: monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy; adjunctive therapy in the treatment of partial seizures, with or without secondary generalisation, in adults, adolescents, and children aged six years and above.

Zonisamide Viatris (previously Zonisamide Mylan) Viatris Limited · Authorised · authorised 31 Mar 2016 · ATC N03AX15

Therapeutic indication (EMA)

Monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy; adjunctive therapy in the treatment of partial seizures, with or without secondary generalisation, in adults, adolescents, and children aged 6 years and above.

Prices — United States and England

SourceProduct as listedPriceUnit / packDate
US NADACZONISADE 100 MG/5 ML ORAL SUSP$2.75055per ML23 Sep 2026
US NADACZONISAMIDE 100 MG CAPSULE$0.10618per EA23 Sep 2026
US NADACZONISAMIDE 25 MG CAPSULE$0.06546per EA23 Sep 2026
US NADACZONISAMIDE 50 MG CAPSULE$0.0955per EA23 Sep 2026
NHS Drug TariffZonisamide 100mg capsules£3.5256 capsule1 Oct 2026
NHS Drug TariffZonisamide 100mg/5ml oral suspension£181.90250 ml1 Oct 2026
NHS Drug TariffZonisamide 25mg capsules£2.3214 capsule1 Oct 2026
NHS Drug TariffZonisamide 50mg capsules£3.4956 capsule1 Oct 2026

NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.

Safety signals and safety-related labeling changes

  • US FDA 13 Apr 2020 ZONEGRAN — safety-related labeling change
    Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide

All safety entries for zonisamide →

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.